125 related articles for article (PubMed ID: 38271834)
1. NRF2 mutation enhances the immune escape of hepatocellular carcinoma by reducing STING activation.
Li C; Liang G; Yan K; Wang Y
Biochem Biophys Res Commun; 2024 Feb; 698():149536. PubMed ID: 38271834
[TBL] [Abstract][Full Text] [Related]
2. Comparative subcellular localization of NRF2 and KEAP1 during the hepatocellular carcinoma development in vivo.
Guerrero-Escalera D; Alarcón-Sánchez BR; Arellanes-Robledo J; Cruz-Rangel A; Del Pozo-Yauner L; Chagoya de Sánchez V; Resendis-Antonio O; Villa-Treviño S; Torres-Mena JE; Pérez-Carreón JI
Biochim Biophys Acta Mol Cell Res; 2022 May; 1869(5):119222. PubMed ID: 35093454
[TBL] [Abstract][Full Text] [Related]
3. Accumulation of phosphorylated p62 is associated with NF-E2-related factor 2 activation in hepatocellular carcinoma.
Shimizu T; Inoue K; Hachiya H; Shibuya N; Aoki T; Kubota K
J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):467-71. PubMed ID: 27246794
[TBL] [Abstract][Full Text] [Related]
4. Molecular Mechanisms Underlying Hepatocellular Carcinoma Induction by Aberrant NRF2 Activation-Mediated Transcription Networks: Interaction of NRF2-KEAP1 Controls the Fate of Hepatocarcinogenesis.
Haque E; Karim MR; Salam Teeli A; Śmiech M; Leszczynski P; Winiarczyk D; Parvanov ED; Atanasov AG; Taniguchi H
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751080
[TBL] [Abstract][Full Text] [Related]
5. NRF2 DLG Domain Mutations Identified in Japanese Liver Cancer Patients Affect the Transcriptional Activity in HCC Cell Lines.
Haque E; Śmiech M; Łuczyńska K; Bouchard MF; Viger R; Kono H; Pierzchała M; Taniguchi H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069882
[TBL] [Abstract][Full Text] [Related]
6. GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway.
Li J; Wang Q; Yang Y; Lei C; Yang F; Liang L; Chen C; Xia J; Wang K; Tang N
J Exp Clin Cancer Res; 2019 Oct; 38(1):438. PubMed ID: 31666108
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway.
Chen J; Jiang S; Shao H; Li B; Ji T; Staiculescu D; He J; Zhao J; Cai L; Liang X; Xu J; Cai X
Sci China Life Sci; 2022 Oct; 65(10):1998-2016. PubMed ID: 35380342
[TBL] [Abstract][Full Text] [Related]
8. Regulation and role of nuclear factor-E2-related factor 2 (Nrf2) in multidrug resistance of hepatocellular carcinoma.
Tian B; Lu ZN; Guo XL
Chem Biol Interact; 2018 Jan; 280():70-76. PubMed ID: 29223570
[TBL] [Abstract][Full Text] [Related]
9. Nrf2 Mutation/Activation Is Dispensable for the Development of Chemically Induced Mouse HCC.
Mattu S; Zavattari P; Kowalik MA; Serra M; Sulas P; Pal R; Puliga E; Sutti S; Foglia B; Parola M; Albano E; Giordano S; Perra A; Columbano A
Cell Mol Gastroenterol Hepatol; 2022; 13(1):113-127. PubMed ID: 34530178
[TBL] [Abstract][Full Text] [Related]
10. Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib.
Yang C; Lu T; Liu M; Yuan X; Li D; Zhang J; Zhou L; Xu M
Phytomedicine; 2023 Mar; 111():154668. PubMed ID: 36657316
[TBL] [Abstract][Full Text] [Related]
11. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
[TBL] [Abstract][Full Text] [Related]
12. Immunoediting of KEAP1-NRF2 mutant tumours is required to circumvent NRF2-mediated immune surveillance.
Baird L; Yamamoto M
Redox Biol; 2023 Nov; 67():102904. PubMed ID: 37839356
[TBL] [Abstract][Full Text] [Related]
13. Fine particulate matter (PM
Li J; Jiang H; Zhu Y; Ma Z; Li B; Dong J; Xiao C; Hu A
Ecotoxicol Environ Saf; 2024 Mar; 272():116052. PubMed ID: 38325274
[TBL] [Abstract][Full Text] [Related]
14. Hydrogen Sulfide Alleviates Liver Injury Through the S-Sulfhydrated-Kelch-Like ECH-Associated Protein 1/Nuclear Erythroid 2-Related Factor 2/Low-Density Lipoprotein Receptor-Related Protein 1 Pathway.
Zhao S; Song T; Gu Y; Zhang Y; Cao S; Miao Q; Zhang X; Chen H; Gao Y; Zhang L; Han Y; Wang H; Pu J; Xie L; Ji Y
Hepatology; 2021 Jan; 73(1):282-302. PubMed ID: 32219872
[TBL] [Abstract][Full Text] [Related]
15. Directly interact with Keap1 and LPS is involved in the anti-inflammatory mechanisms of (-)-epicatechin-3-gallate in LPS-induced macrophages and endotoxemia.
Chiou YS; Huang Q; Ho CT; Wang YJ; Pan MH
Free Radic Biol Med; 2016 May; 94():1-16. PubMed ID: 26878775
[TBL] [Abstract][Full Text] [Related]
16. NRF2: KEAPing Tumors Protected.
Pillai R; Hayashi M; Zavitsanou AM; Papagiannakopoulos T
Cancer Discov; 2022 Mar; 12(3):625-643. PubMed ID: 35101864
[TBL] [Abstract][Full Text] [Related]
17. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
18. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation.
Gong M; Li Y; Ye X; Zhang L; Wang Z; Xu X; Shen Y; Zheng C
Cell Commun Signal; 2020 Jun; 18(1):98. PubMed ID: 32576270
[TBL] [Abstract][Full Text] [Related]
19. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells.
Sun X; Ou Z; Chen R; Niu X; Chen D; Kang R; Tang D
Hepatology; 2016 Jan; 63(1):173-84. PubMed ID: 26403645
[TBL] [Abstract][Full Text] [Related]
20. Andrographolide Activates Keap1/Nrf2/ARE/HO-1 Pathway in HT22 Cells and Suppresses Microglial Activation by A
Seo JY; Pyo E; An JP; Kim J; Sung SH; Oh WK
Mediators Inflamm; 2017; 2017():5906189. PubMed ID: 28373747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
